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subsequent progression to focal glomerular sclerosis
AGNES FoGo, EDITH P. HAWKINS, PHILLIP L. BERRY, ALAN D. GLIcK, MY1t. L. CHIANG,
ROBERT C. MACDONELL, JR., and IEKUNI ICHIKAWA
Departments of Pathology and Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee and Baylor College of Medicine,
Houston, Texas, USA
Glomerular hypertrophy in minimal change disease predicts subse-
quent progression to focal glomerular sclerosis. The study sought a
diagnostic clue to identify the group of pediatric patients with apparent
minimal change disease who subsequently develop focal glomerular
sclerosis (FGS). Review of all renal biopsy material at our institutions
identified 42 pediatric patients who met the standard criteria for minimal
change disease (MCD) on initial biopsies. Of those, 10 deteriorated
clinically and on rebiopsy showed focal glomerular sclerosis (FGS). The
initial renal biopsies of these 10 patients were analyzed morphometri-
cally to determine the mean glomerular tuft area (GA). The results were
compared to those of the remaining 32 patients whose subsequent
benign clinical course was consistent with MCD, and to randomly
selected, age-matched autopsy controls without renal disease (CONT,
N = 10). The mean age was comparable among the three groups
studied. Separate groups of adult (N = 12) and pediatric (N 18)
patients with initial biopsies with FGS were also studied. The initial
biopsy of pediatric patients who subsequently showed FGS (rebiopsy
performed on average 3.3 years later) had an average GA of 13.5 x lO
mm2, 76% larger than glomeruli from children with MCD (7.7 x l0-
mm2, P < 0.0005) and 62% larger than CONT (8.4 x l0- mm2, P <
0.005). Patients with FGS on initial biopsy, whether adult or pediatric,
also had significantly larger GA than the age-matched MCD or CONT
groups. Evaluation of GA in all the 42 pediatric biopsies with initial
MCD further showed that in 23 patients GA was equal to or smaller than
the CONT average. Of these, one (4%) was found at the rebiopsy to
have FGS, Fifteen patients had GA 1.00 to 1.75 X the CONT average;
five (33%) of these were found at the rebiopsy to have FGS. Finally,
four had GA >l.75x the CONT average at the initial biopsy, all of
whom (100%) were found to have FGS at the rebiopsy. The presence of
glomerular hypertrophy in biopsies of apparent MCD, therefore, ap-
pears to be a highly specific indicator of increased risk for progression
to FGS. The data are supportive of the view that the subset of MCD
which develops FGS represents a distinctive entity in which pathophys-
iologic mechanism(s) promoting glomerular hypertrophy are imposed.
Minimal change disease (MCD) is the most common patho-
logical entity underlying nephrotic syndrome in the pediatric
population [1—4] and accounts for 10 to 30% of nephrotic
syndrome in adult patients [5, 6]. Prerequisite for the diagnosis
of MCD is the exclusion of abnormal findings at the light
microscopic level such that the presence of even a single
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segmentally sclerotic glomerulus in a biopsy specimen warrants
a diagnosis of focal glomerulosclerosis (FGS). The latter, in
contrast to MCD, is often resistant to glucocorticoid therapy
and carries a substantial risk of progression to end-stage renal
disease. Of particular relevance to this study, it has been
documented by repeated renal biopsies that some patients with
apparent MCD at the initial biopsy progress to FGS [7—9].
However, it has been postulated that in the particular subset of
patients who progresses to FGS from apparent MCD, initial
biopsy sampling may not have been adequate and may have
missed glomeruli with already existing sclerotic lesions. Alter-
natively, it is conceivable that although FGS was indeed absent
at the time of initial biopsy, abnormal pathogenic processes had
already come into play in this unique MCD subset, leading
subsequently to development of morphologically identifiable
FGS, detected only at the rebiopsy. Identification of even a
subtle sign indicative of such abnormal pathogenic processes at
the initial biopsy would allow diagnosis of this high risk subset
of MCD and offer reassurance to those patients without such
signs who have a benign prognosis. Numerous studies have
attempted to define this unique population with poor prognosis.
Morphological signs which have been proposed to identify the
high risk subset of MCD include widespread 1gM deposits (1gM
nephropathy) and diffuse mesangial hypercellularity [10—19].
Numerous studies of 1gM nephropathy have presented con-
flicting data on whether there is increased risk of glucocorticoid
dependence or resistance, or increased risk of progressing to
renal failure in these patients [10—15]. Diffuse mesangial hyper-
cellularity is seen in —3% of biopsied children with nephrotic
syndrome [4, 16, 17]. Although these patients may be resistant
to glucocorticoid therapy, no decline in renal function was seen
in one series [18], whereas in another study of 26 children,
apparent transition to FGS was seen in one of four rebiopsied
patients [16]. Previous studies focusing on the findings of
epithelial cell vacuolization [19, 20] in MCD and FGS, showed
that although this feature coincided closely with the presence of
FGS lesions at the time of biopsy, it failed to identify the
specific MCD patient population which subsequently developed
FGS.
In the past decade, several potential pathophysiologic mech-
anisms leading to glomerulosclerosis have been explored exten-
sively in experimental animal models, with focus on such
diverse areas as hyperfiltration [21], abnormal traffic of macro-
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molecules in the mesangium [22, 23], plasma lipid abnormalities
[24] and glomerular hypertrophy [25—281. In considering these
factors, it is obviously impossible with the currently available
technology to assess hyperfiltration at the single nephron level
in humans. The effects of hyperlipidemia in animal studies are
difficult to extrapolate to the human settings discussed here, as
hyperlipidemia is equally present in nephrotic syndrome due to
FGS and typical MCD. In our recent studies in an animal model
of FGS [27], the size of glomeruli was found to change in a
biphasic pattern, that is, increases at the early stage of FGS
development followed by a reduction as the sclerotic lesion
advances. Given that the existence of this tight correlation
between glomerular hypertrophy and early sclerotic changes
appears ubiquitous in many other experimental settings as well
[28—34, Note added in proofi, we hypothesized that the glomer-
uli of the unique MCD subset in which early processes leading
to sclerosis had already commenced, might also display glomer-
ular hypertrophy. If this is indeed the case, the presence of
glomerular hypertrophy in the biopsy specimens of apparent
MCD could identify those patients with increased risk for
sclerosis and progressive renal disease.
Methods
Patient selection
All pediatric (<13 years old) and adult renal biopsies in our
files at Vanderbilt University Hospital with diagnosis of mini-
mal change disease (MCD) or focal glomeruloscierosis (FGS)
(pediatric and adult) were reviewed. The pediatric renal biopsy
files at Texas Children's Hospital were reviewed to identify all
patients with an initial diagnosis of MCD, and nine patients with
FGS who met our study criteria. Patients met standard WHO
criteria for diagnosis [35], and had tissue for light microscopy,
immunofluorescence and electron microscopic studies. Renal
biopsies were immersion fixed in formalin or Zenker's, proc-
essed routinely, embedded in paraffin and 2 to 3s thick sections
were cut and examined. Only patients with a minimum of seven
glomeruli available for morphometric analysis were included for
further evaluation. Patients with history or diagnosis of diabetes
mellitus, cyanotic heart disease, massive obesity, interstitial
nephritis or autoimmune disease were excluded, as were pa-
tients receiving prolonged (>5 years) glucocorticoid therapy
before initial biopsy. Subclasses of minimal change disease
were not included (that is, 1gM nephropathy, diffuse mesangial
hypercellularity), and cases of MCD with immunofluorescence
positivity were also excluded.
Control specimens were obtained from randomly-selected
age-matched autopsy patients who did not have clinical history
or pathologic evidence of diabetes mellitus, significant cardio-
vascular disease, massive obesity or renal disease. The majority
of these patients had sudden catastrophic illnesses, and patients
with prolonged, protracted debilitating illnesses were excluded.
Causes of death in the pediatric controls were: encephalitis,
sepsis, viral illness (2), bronchopneumonia, atrial puncture by
central line, drowning, motor vehicle accident, sudden death
and Reye's syndrome. Causes of death in the adult controls
were: Pseudomonas aeruginosa sepsis, basilar skull fracture,
ventricular fibrillation, Staphylococcus aureus pneumonia, mo-
tor vehicle accident (2), ruptured intracerebral berry aneurysm
(2) and ruptured pharyngeal artery. Autopsy tissue was fixed in
Table 1. Clinical data in adult patients and controls
Diagnosis N
Age
(years)
Sex Number of
glomeruliM F examined
Interval
to 1st Bx
(months)
Initial Sr
mg/dl
MCD 8 46±5
[28—69]
2 6 18±4
[14—38]
2±0
[1—3]
1.5±O.5
FGS 12 39±4
[20—68]
7 5 13±2
[7—32]
13±8
[1—84]
l.7±0.9a
Control 9 40 6
[19—69]
5 4 30 8
[20—771
N/A N/D
Abbreviations are: M, male; F, female; Bx, renal biopsy; Se,., serum
creatinine concentration; MCD, minimal change disease; FGS, focal
glomerular sclerosis; N/A, not applicable; N/D, not determined. Values
are expressed as mean 1 SE.
a Initial Sr was available in 6 of 8 MCD and 7 of 12 FGS patients.
formalin and processed routinely, and 3 s thick sections were
examined.
In the second portion of our study, all pediatric patients with
an initial diagnosis of minimal change disease by renal biopsy
and a subsequent second biopsy showing progression to focal
glomeruloscierosis (abbreviated as MCD-FGS) who were iden-
tified at our institutions were evaluated, and compared to those
MCD patients without progression either clinically or by rebi-
opsy (abbreviated as MCD-MCD) and to age-matched controls.
Morphometry
A single section of each patient's initial biopsy was analyzed,
using a digital planimeter (Donsanto Corporation, Massachu-
setts, USA). All non-hyalinized glomeruli on a single thin
section were measured by tracing the outline of the glomerular
tuft, and the mean glomerular area was calculated for that
patient. In autopsy specimens, a comparable area was marked
randomly with an ink pen on the glass slide, and all non-
hyalinized glomeruli within this area were then measured to
give the mean glomerular area for these patients. The single
largest glomerulus measured was also identified in each speci-
men as another index of the glomerular hypertrophy in that
patient. All biopsies were examined without knowledge of the
clinical outcome.
Follow-up
Clinical follow-up was obtained in pediatric patients by chart
review and, when possible, consultation with the nephrologist
and primary referring physician.
Statistical analysis
Results were compared by one-way ANOVA followed by
unpaired Student's t-test, and were deemed statistically signif-
icant if P < 0.05. Results are given as mean SE.
Results
Adult patients
In the initial phase of our study, we evaluated twenty adult
patients, twelve of these with focal glomeruloscierosis (5
women and 7 men) and eight with minimal change nephrotic
syndrome (6 women and 2 men; Table 1). The adult control
group consisted of nine age-matched autopsy patients (4 women
and 5 men; Table 1). As shown in Table 1, the mean ages of 39
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Fig. 1. Valuesfor mean glomerular areas in adult patient and control
groups. Values for mean glomerular areas were determined on adult
autopsy (CONT) and biopsy specimens, the latter shown to have
histological findings conforming to the criteria of minimal change
disease (MCD) or focal glomerular sclerosis (FGS). Each data point
represents data from each patient or control. Mean values are shown by
vertical bars.
to 46 years were comparable among the three groups. Docu-
mentable proteinuria was present on the average for 13 months
preceding the initial biopsy in the focal glomerulosclerosis
patients, compared to two months in MCD patients.' Serum
creatinine levels were, on average, slightly elevated, but essen-
tially identical between groups (Table 1). The mean number of
glomeruli examined on autopsy or biopsy specimens was on
average 30 8 in control, 18 4 in MCD and 13 2 in FGS.
Mean glomerular area, GA, assessed in specimens from each
patient and control, is illustrated in Figure 1. Values for GA in
MCD are smaller than those of controls (average: 13.0 1.6 x
l0— mm2 vs. 15.8 0.8, P < 0.05), reflecting, presumably, the
higher female to male ratio in the MCD group, since glomerular
size in normal adults has been previously reported to be smaller
in females [36], and there was a trend for our male controls to
have larger glomerular size (16.2 x iO vs. 15.3 x l0 mm2,
male vs. female control). In contrast, patients with FGS had
substantially and significantly higher values for mean GA (av-
erage: 19.9 1.6 x l0— mm2), on average 25% larger than
autopsy controls (P < 0.025) and 54% larger than MCD group
(P < 0.005). As indicated by the individual data points in Figure
1, however, a substantial overlap is present between MCD and
FGS groups. Nevertheless, the majority of FGS patients had
This difference in intervals between the detection of proteinuria and
the initial biopsy appears to reflect the current common practice to
perform a renal biopsy promptly in adults with nephrotic syndrome,
since adult patients are more likely to have underlying glomerulone-
phritis rather than MCD as a cause for their nephrotic syndrome. In
contrast, adult FGS often presents as a gradual deterioration of renal
function, and thus renal biopsy may be performed at a later date.
mean glomerular areas substantially larger than the average of
either control or MCD patients. Analysis of the area of the
largest glomerulus from each specimen showed a similar trend:
Areas of these largest glomeruli averaged 31.0 2.7 x l0—
mm2 in FGS versus 20.3 1.1 in MCD (P < 0.005) and 24.7
1.7 in controls (P < 0.05 FGS vs. control, P < 0.005 FGS vs.
MCD). The range of the largest glomerulus' area was, however,
quite wide: 18.5 to 49.3 x iO mm2 in FGS, 16.7 to 27.0 in
MCD and 16.0 to 33.6 in controls. Thus, overlap remained
similar between groups whether comparing mean or maximum
glomerular areas.
Pediatric patients
Pediatric FGS was studied in two groups: nine patients with
initial diagnosis of FGS (4 boys, 5 girls) from Vanderbilt
University Hospital [FGS( VU)] and a group of nine older FGS
patients diagnosed at Texas Children's Hospital. [FGS(TC)]. In
the second phase of our investigation, we studied 32 pediatric
patients with initial diagnosis of MCD who continued to have
_______
benign clinical follow-up courses consistent with MCD (MCD-
MCD, 25 boys, 7 girls) and 10 patients with initial biopsy
diagnosis of MCD who had biopsy-proven FGS later (MCD-
FGS, 7 boys, 3 girls). Ten autopsy patients (6 boys, 4 girls) were
studied as controls. The mean age was similar for all groups,
ranging from 4.9 to 5.6 years, except for the FGS (TC) patients
who were slightly, but significantly older (P < 0.05) and are
therefore analyzed separately and compared to an age-matched
subset of the autopsy control patients.
All initial creatinine clearances available (in 5 of the 10
MCD-FGS patients, 13 of the 18 FGS patients and 10 of the 32
MCD-MCD group) were within normal range. Serum creatinine
was slightly elevated only in the FGS group. Proteinuria was
present on average 13 to 19 months before biopsy in the
younger patients. The older group was biopsied after a shorter
interval2 due to failure to respond to glucocorticoid therapy in
combination with features atypical for MCD, such as hyperten-
sion and marked hematuria. Intermittent hypertension and/or
fluid overload were present before biopsy in 12 of the 24
MCD-MCD patients in whom prebiopsy treatment data were
available, requiring therapy with diuretics in 10 patients, reser-
pine in one patient and no drug in one patient. One of the 10
MCD-FGS patients had hypertension before the initial biopsy,
not requiring therapy. Six of the nine FGS(VU) patients re-
quired diuretic therapy for intermittent fluid overload and
associated increased blood pressure. Five of the nine older
FGS(TC) patients had hypertension before biopsy, requiring
therapy with diuretics, and in combination with reserpine in
one, propranolol in one, methyldopa in one, and hydralazine
and propranolol in one patient.
The mean number of glomeruli examined on autopsy or
biopsy specimens was 39 7 in control, 28 2 in MCD-MCD,
21 3 in FGS(VU), 29 6 in FGS(TC) and 20 4 in
MCD-FGS. Juxtamedullary glomeruli were included in the
majority of the specimens. The mean glomerular area in these
2 The differences in these intervals reflect the clinical recognition of
the nephrotic syndrome, with current practice being to biopsy only
those patients who do not respond as expected to glucocorticoid
therapy.
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Fig. 2. Values for mean glomerular areas in pediatric patient and
control groups. Values for mean glomerular areas were determined on
pediatric autopsy (CONT) and initial biopsy specimens. Results from
initial biopsies were divided into two groups: one from patients whose
initial biopsy findings conformed to the criteria of minimal change
disease, yet rebiopsy findings were consistent with focal glomerular
sclerosis (MCD-FGS), the other from patients whose initial biopsy
findings also conformed to the criteria of MCD and had subsequent
clinical courses typical for MCD (MCD-MCD). Each data point repre-
sents data from each patient or control. Mean values are shown by
vertical bars.
pediatric patients is shown in Figure 2. The initial and subse-
quent biopsies of one of these patients are illustrated in Figure
3. MCD-MCD and autopsy control glomerular areas were not
significantly different, 7.7 0.4 x i0 mm2 and 8.4 0.5,
respectively. In contrast, FGS (VU) patients had substantially
and significantly increased glomerular areas, 10.7 1.5 x iO
mm2, 27% larger than control and 39% larger than MCD (P <
0.005). The older FGS(TC) patients also showed marked gb-
merular hypertrophy, mean glomerular size was 15.4 1.1 X
i0 mm2, substantially larger than MCD-MCD or the mean
size of autopsy controls of the same age (N = 5, mean 9.6 x
l0— mm2; P < 0.005). The mean glomerular area of the initial
biopsies in MCD-FGS patients was substantially and signifi-
cantly greater than either MCD-MCD or autopsy patients;
averaging 13.5 1.3 x iO mm2, a value 62% greater than that
of controls (P < 0.005) and 76% greater than MCD-MCD' s (P <
0.0005; Fig. 2).
Clinical follow-up
MCD without progression (MCD-MCD). Clinical follow-up
data were available in all but one of these 32 pediatric patients.
Sixteen of the 32 MCD-MCD patients have been treated with
prednisone only, while 15 received additional cytotoxic therapy
(chiorambucil or cyclophosphamide). Nineteen of the patients
remain glucocorticoid-dependent, while 11 reached remission
and were taken off medication. Two patients had persistent
nephrotic syndrome resistant to prednisone and cytotoxic ther-
apy. In eight of these 32 patients, a second biopsy was done,
Fig. 3. Initial renal biopsy in minimal change disease with subsequent
progression. This 5-year-old girl's initial biopsy, middle panel, was
indistinguishable from MCD, except for substantial gbomerular hyper-
trophy vs. age-matched typical MCD with subsequent benign clinical
course (MCD-MCD, top panel). Her subsequent biopsy, bottom panel,
50 months later, showed FGS. (Jones' silver stain, X 160).
and in three a third biopsy was performed because of multiple
relapses (Table 2). All the rebiopsies confirmed the diagnosis of
MCD with one showing diffuse mesangial hypercellularity. The
eight rebiopsied patients with persistent MCD were treated as
follows after the second biopsy: four received prednisone only,
of these one reached remission off therapy; and three had
glucocorticoid-sensitive relapses. Two required reserpine or
methyldopa for transient hypertension. One of the eight rebi-
opsied MCD-MCD patients received no additional treatment
and is in remission. Three of these eight patients received
cytotoxic therapy, one of whom is in remission off therapy and
the remaining two having glucocorticoid-responsive relapses.
As of September 5, 1989 all 31 of the 32 MCD-MCD patients
with clinical follow-up have normal renal function, as defined
by normal serum creatinine level and/or creatinine clearance
rate.
FGS on initial biopsy [FGS(VU) and FGS(TC)]. Follow-up
was available in seven of the FGS(VU) patients, all of whom
were treated before biopsy with prednisone and received addi-
tional cytotoxic therapy (cyclophosphamide and chlorambucil)
after biopsy. Two patients are currently in remission (for 6
years and 1.5 years, respectively) with normal renal function on
low dose prednisone. Two patients developed end stage disease
0)
x
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a
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Table 2. Clinical data in pediatric patients and controls
Diagnosis N
Age
(years)
Number ofSex glomeruliM F examined
Interval
to 1st Bx
months
Initial
Sr
,ng/dl
Interval Interval
to 2nd Bx to 3rd Bx
months
Cytotoxic
Tx
.Renal Function
Norm Mild F-Stage
MCD-MCD 32 4.9 0.5
[1.1—12.9]
25 7 28 2
[10—621
13 4
[0—84]
0.5 0.0 50 13 52 26
[8—108] [21—1031N=8 N=3
15 31 0 0
FGS(VU) 9 3.6 0.8
[1.4—9.0]
4 5 21 3
[13—391
13 9
[2—77]
0.9 0.4 N/D N/A 7 5 0 2
FGS(TC) 9 6.2 1.3
[1.1—11.8]
7 2 29 6
[9—56]
2.1 0.4
[1—5]
0.6 0.1 24 8 46 27
[6—52] [19—73]N=5 N=2
8 6 0 3
MCD-FGS 10 5.6 1.0
[2.4—12.5]
7 3 20 4
[8—43]
19 7
[0—58]
0.6 0.1 40 6 52 12
[15—72] [19—103]N=10 N=6
10 3 3 4
Control 10 5.0 1.0
[1.3—9.0]
6 4 39 7
[23—80]
N/A N/D N/A N/A N/A N/A N/A N/A
Abbreviations are: M, male; F, female; Bx, renal biopsy; Sr, serum creatinine concentration; Tx, therapy; Norm, normal; F-Stage, end-stage;
MCD, minimal change disease; FGS, focal glomerular sclerosis; VU, Vanderbilt University Medical Center; TC, Texas Children's Hospital; N/A,
not applicable; N/D, not determined.
a Clinical follow-up data were available for 31 of 32 MCD-MCD patients, and for 7 of 9 FGS(VU) patients, and for all patients in the other groups.
Values are expressed as mean I SE.
one and three years after biopsy; one of these died and the other
received a transplant and is now on dialysis after rejecting the
graft. The remaining three patients have persistent proteinuria
and normal renal function 1.5 to seven years after biopsy.
Five of the nine FGS(TC) patients had received prednisone
before the biopsy, and six received additional cytotoxic agent
(cyclophosphamide, chiorambucil or azathioprine) after diagno-
sis. Five of these nine patients were biopsied a second time, and
two were biopsied a third time, confirming the initial diagnosis
of FGS. Three patients developed end-stage renal disease, from
5 to 12 years after initial diagnosis; two are on dialysis and one
patient received a transplant. Two patients are in remission and
four have persistent proteinuria with normal renal function, two
to seven years after diagnosis.
MCD patients with progression to FGS (MCD-FGS). Indica-
tions for rebiopsy were continued relapses (N = 10) and failure
to respond to treatment (N = 6). Hypertension was present in
four of ten at rebiopsy, whereas only one patient had hyperten-
sion on entry in this group. These four patients were treated
with diuretics; in addition one patient required reserpine and
one patient propranolol and diuretics to normalize blood pres-
sure. Three additional patients became hypertensive later in
their course, after the diagnosis of FGS on second biopsy. The
mean serum creatinine at the time of second biopsy, determined
in eight patients, was 1.4 mgldl, with elevated levels in only two
patients. The average length from initial clinical presentation to
second biopsy which showed FGS was 4.9 years (range 1.4 to 9
years). The average interval from initial biopsy with apparent
MCD until the second biopsy of FGS was 3.3 years (range 1.3
to 6 years; Table 2). Six patients were treated with prednisone/
cytotoxic combination therapy (chlorambucil or cyclophospha-
mide) after the first biopsy. The cytotoxic drug was changed in
three of these six patients (to chlorambucil, azathioprine or
cyclophosphamide) after the second biopsy. Two of these three
developed end stage disease; one has mild renal insufficiency at
latest follow-up. The other three patients who were treated
initially with cytotoxic drugs, received only prednisone after
the second biopsy. Two of these developed mild renal insuffi-
ciency, one developed end stage disease. Three patients re-
ceived only prednisone after the initial biopsy and prednisone +
cytotoxic therapy after the second biopsy. Of these patients,
one had subsequent multiple relapses, one reached complete
remission and has now been off medication for more than five
years, and one developed end stage disease. In one patient, no
therapy was given until after the second biopsy, when pred-
nisone + cytotoxic therapy was started. This patient also
reached clinical remission. A third biopsy was performed in six
of the ten patients, on average 4.3 years after the second biopsy
(range 1.6 to 8.6 years), uniformly confirming the second biopsy
diagnosis of FGS.
In summary, of these 10 patients with progression of MCD to
FGS, three have normal renal function and two of these patients
are in remission as of September 5, 1989 (11.5 and 4 years,
respectively, after initial biopsy), three patients have mild renal
insufficiency and four have had end-stage renal disease, two of
the latter are on dialysis and two have received a renal
transplant.
Index predicting the outcome after initial biopsy findings of
MCD in pediatric patients
The aim of this analysis was to define the risk of developing
FGS among patients with apparent MCD on renal biopsy. To
calculate the probability of developing FGS at a given glomer-
ular size in the initial biopsy, we assessed both 1) glomerular
area at initial biopsy and 2) incidence of subsequent FGS among
these biopsied patients, by analyzing the entire biopsy popula-
tion at our institutions with apparent MCD on initial biopsy.
This analysis thus included both patients with initial apparent
MCD followed by a subsequent course typical of MCD (N = 32)
and patients with initial apparent MCD followed by subsequent
progression to FGS proven by second biopsy (N 10). Gb-
merular area for each of these patients was compared to the
mean glomerular area of normal age-matched autopsy controls.
The patient population was divided into those with initial
glomerular size less than mean control; those with glomerular
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Fig. 4. Risk of progression of MCD in pediatric patients. Calculated
indices give the probability of pediatric patients (1.1 to 12.9 years old)
who are shown to have morphologic findings consistent with minimal
change disease at the initial biopsy to develop focal glomerular sclerosis
(MCD-FGS, solid bars) subsequently or to continue to show benign
clinical signs consistent with minimal change disease (MCD-MCD,
hatched bars). X axis represents the size of mean glomerular area
obtained in the initial biopsy material relative to mean control (1.3 to 9.0
years old) value.
area between 1.00 to 1.75 times the mean control, and those
with glomerular area larger than 1,75 times the control. Inci-
dence of progression to FGS was then calculated for each
patient within each of these relative glomerular area intervals
(Fig. 4).
Twenty-three patients had glomerular area less than mean
autopsy control; only one of these developed FGS (1/23, 4.3%).
Thus, the probability of continued MCD in these patients with
smaller than average glomerular area was 95.7%. Fifteen pa-
tients had glomerular area 1.00 to 1.75 x control; of these five
developed FGS (5/15, 33.3%). All four patients with glomerular
size greater than 1.75 x control had progression to FGS (4/4,
100%).
Discussion
Unlike other renal morphological features, the size of the
glomerulus is expected to vary widely among age groups in the
pediatric population. In our study with this population, how-
ëvér, the need for a sizable population required for meaningful
analyris precluded comparisons among patients and control
groups withina narrow age range. As shown in Table 2, patients
ranging in age from 1.1 to 12.9 years old were included in our
study. Expectedly, therefore, values for glomerular area, GA,
of controls varied widely as shown in Figure 2. The initial phase
of our study in adults was undertaken to avoid this undesirable
variability already set into the design of investigation. Of
interest, however, values for GA of adult control samples (Fig.
1) scattered to an extent similar to that found in pediatric
controls (Fig. 2). The analysis made subsequently between
males and females revealed that this wide range was largely due
to the male-to-female difference, a situation unique to the adult
population [36]. In fact, average GA values of adult MCD
patients, which consisted largely of females, was significantly
lower than that of adult controls, a phenomenon not seen in the
pediatric population (Fig. 2).
Values for GA in adult FGS were significantly larger than
those of controls and MCD although, because of the wide
scatter present in all groups, a substantial overlap was evident
between FGS versus controls or MCD. Similarly, mean GA was
significantly larger in pediatric FGS versus control or MCD
patients. Nonetheless, the observed larger mean GA values in
our FGS patients are even more impressive when one considers
that the calculation of these mean values include glomeruli with
severe sclerosis. This higher GA value is expected to be
progressively diminished as FGS advances [271, that is, as
serum creatinine increases to a level much higher than the mean
of — 1.7 mg!dl seen in our adult FGS patients. In this regard, GA
in pediatric FGS, although enlarged, did not show as marked
hypertrophy as MCD-FGS.
Most importantly, our analyses of the initial biopsy/autopsy
specimens in pediatric groups revealed that GA values of MCD
patients who subsequently developed FGS were significantly
and markedly greater than those of the other groups. As in adult
FGS patients, values from these pediatric patients with transi-
tion from MCD to FGS showed some overlap with those of the
other two groups. In analogy to the adult's situation, this
overlap within the pediatric population would be substantially
lessened if a large number of samples were available from each
category to allow group-to-group comparisons at a much nar-
rower age range than that employed in our study.
As stated earlier, one may argue that those found to have
FGS on a second biopsy represent particular circumstances
where glomeruli with sclerotic lesions detected at the second
biopsy were not appropriately sampled at the initial biopsy.
Evidence against this possibility is available in Table 2. That is,
when six patients who were diagnosed with FGS by a second
biopsy were rebiopsied subsequently, none was found to have
changed to MCD, suggesting that the change between histolog-
ical appearance of MCD and FGS is unidirectional from MCD
to FGS. The transition from MCD to FGS seen in our study
was, therefore, highly unlikely to be merely a result of variabil-
ity at the level of biopsy sampling, which would be expected to
produce bidirectional changes. Unequivocal evidence for oc-
currence of transition from MCD to FGS in animals has
recently been obtained in experimental models which initially
show glomerular damage mimicking symptomatically, morpho-
logically and biochemically typical human MCD [37, 38], and
subsequently develop progressive deterioration of glomerular
function and evolution of sclerotic lesions [39].
Our analysis of probability index has shown that the mea-
surement of GA is a highly specific test for predicting the
prognosis in MCD, as all patients who had a subsequently
benign MCD course had initial GA l.75 x mean control (100%
specificity). Thus, the predictive value of a positive test, that is,
the percentage of patients with GA >1.75 mean control who
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Fig. S. Risk of progression of MCD in pediatric patients <5 years old.
Calculated indices give the probability of 1 to 5 year old patients who
are shown to have morphologic findings consistent with minimal change
disease at the initial biopsy to develop focal glomerular sclerosis
(MCD-FGS, solid bars) subsequently or to continue to show benign
clinical signs consistent with minimal change disease (MCD-MCD,
hatched bars). X axis represent the size of mean glomerular area
obtained in the initial biopsy material relative to mean control (1 to 5
years old) value.
develop FGS, is 100%, and the predictive value of a negative
test (percentage of patients with GA l.75 who do not develop
progression) is 84%. However, using this cut-off, the number of
the patients with this feature at the initial biopsy who developed
FGS was only four out of ten (40% sensitivity). In light of the
above-discussed limitation imposed on our study, that is, sam-
pies from patients with wide age range were compared with a
single mean value calculated from autopsy specimens from
individuals with a similarly wide age range, the sensitivity of
our test has a potential to be improved further. That is, if the
mean control value is established for finite age ranges from 1
year to 13 years of age, the sensitivity can be improved by
lowering the "cut-off" level without sacrificing the high speci-
ficity.
Thus, the GA value from both MCD-MCD and MCD-FGS
patients can be compared with, and expressed as a size relative
to, the mean of exactly age-matched autopsy controls. For
example, GA value from a very young patient with initial MCD,
who is destined to develop FGS, may be found to be substan-
tially greater than his/her closely age-matched controls although
it may be similar to, or even smaller than, our single mean
control value obtained from children I to 13 years of age.
Separate analysis of the younger pediatric group (5 years, N
= 27) indeed shows this trend (Fig. 5). Of these patients who
had MCD at the initial biopsy, seven developed FGS. Glomer-
ular area was >1.5-fold greater in five of these seven patients
than the mean of their 5 year old controls (N = 5; 71%
sensitivity).3 Only two of 22 patients less than five years old
with glomerular area less than 1.Sx mean autopsy control
developed progression. Of the 20 patients who were in the
MCD-MCD category, none had glomerular area >1.5 x con-
trols at the initial biopsy (100% specificity).4 Although extensive
morphometric measurements based on a large number of nor-
mal autopsy control specimens would be involved to establish
the control values for finite age ranges required for even more
accurate analysis, our results clearly warrant such an effort.
Overall, our results are supportive of the view previously
proposed by others [40—421 that the pathophysiologic mecha-
nism underlying FGS is distinct from benign MCD. Further, our
studies are indicative of the pathophysiologic importance of
mechanisms linked to glomerular hypertrophy in the develop-
ment of FGS. While such a close association between glomer-
ular hypertrophy and sclerosis has been demonstrated in a
variety of experimental settings with animals, using nephrec-
tomy [26—30], dietary manipulations [291 and drugs [27], the
association has also been reported in humans (Note added in
proof). Thus, glomerular sclerosis in individuals who underwent
nephrectomy early in life has been noted as incidental autopsy
findings [43—51], and patients with oligomeganephronia, a pe-
culiar infant disease characterized by a marked glomerular
hypertrophy [521, are known to develop glomerular sclerosis.
More recently, EI-Khatib, Becker and Kincaid-Smith in their
histological studies with reflux nephropathy have found a close
positive correlation between the degree of azotemia and the size
of glomeruli in biopsy specimens [53]. In this regard, a variety
of cytokines and vasoactive substances are known to promote
mesangial cell growth in vitro [54—56], with some most recently
shown to have the capacity to stimulate mesangial matrix
release as well [54, 56]. Moreover, in a recent study with
transgenic mice [60] in which human growth hormone is ex-
pressed, investigators found that a high mortality rate resulting
from glomerular sclerosis coincided with marked glomerular
hypertrophy. It is therefore speculated that circulating/local
cytokines or other growth promoting substances possessing the
capacity to enhance both glomerular hypertrophy and mesan-
gial matrix formation, underlie the development of excessive
accumulation of extracellular matrix in the mesangium region,
which ultimately lead to the typical glomerular sclerotic pat-
tern. Our research is, however, still distant from identifying
specific substance(s) causing these changes in animals and
humans as well.
In summary, our results define the risk for progressive renal
disease based on the presence of glomerular hypertrophy in
renal biopsies of patients with apparent MCD, thus directing
vigilant follow-up of high risk patients and reassurance of
patients with a good prognosis.
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